Meeting
2020 ASCO Virtual Scientific Program
Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide.
Authors
Bora Lim
The University of Texas MD Anderson Cancer Center, Houston, TX
Bora Lim , Sahil Seth , Lei Huo , Rachel M. Layman , Vicente Valero , Alastair Mark Thompson , Jason B White , Jennifer Keating Litton , Senthil Damodaran , Rosalind P Candelaria , Banu Arun , Gaiane M Rauch , Rashmi Krishna Murthy , Qingqing Ding , William Fraser Symmans , Li Zhao , Jianjun Zhang , Debu Tripathy , Stacy L. Moulder , Naoto T. Ueno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02689427
Citation
J Clin Oncol 38: 2020 (suppl; abstr 517)
DOI
10.1200/JCO.2020.38.15_suppl.517
Abstract #
517
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC.
First Author: Sahil Seth
Poster
2020 ASCO Virtual Scientific Program
Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes.
First Author: Reva K Basho
Poster
2019 ASCO Annual Meeting
Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443).
First Author: Sahil Seth
Poster
2020 ASCO Virtual Scientific Program
Germline alterations other than BRCA in triple negative breast cancer (TNBC) patients who underwent neoadjuvant therapy (NAT) on a prospective clinical trial.
First Author: Banu Arun